Choose VUMERITY® first

  • Strong efficacy for patients starting or switching therapy
  • Well-understood safety profile
  • Flexibility of a treatment that can go everywhere they go
Complete a Start Form today
  • The efficacy of VUMERITY is based upon bioavailability studies comparing dimethyl fumarate (DMF) to VUMERITY in patients with relapsing forms of MS and healthy subjects1
  • VUMERITY offers the established efficacy of DMF across Studies 1 and 2
  • In Study 1 and Study 2 pivotal trials, DMF demonstrated a 53% and 44% relative reduction in annualized relapse rate (ARR) vs placebo, respectively (0.172 vs 0.364; P<0.0001), (0.224 vs 0.401; P<0.0001)1
  • Most common adverse reactions (incidence for DMF ≥10% and ≥2% more than placebo) were, respectively, flushing (40% and 6%), abdominal pain (18% and 10%), diarrhea (14% and 11%), and nausea (12% and 9%)

MORE PATIENTS HAVE STARTED VUMERITY
THAN ANY OTHER BRANDED ORAL THERAPY FOR RMS IN THE US SINCE DECEMBER 20202,a

aBased on the cumulative number of new MS prescriptions for the months December 2020 through February 2023 per IQVIA NPA New to Brand, Patient Insights® monthly NBRx.

VUMERITY offers your patients:

Efficacy and safety outcomes
from switch patients

Switching to VUMERITY study

Well-established, real-world safety

Long-Term Study

Persistence and
refill adherence data

Real-World Study

Consistent support for
eligible patients

Coverage and Access